Short answer
Stoke Therapeutics, Inc. (STOK) filed an 8-K current report with the SEC on September 25, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Edward M. Kaye resigning as Class III director and R&D Committee member effective September 23, 2026.
Stoke Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Edward M. Kaye resigning as Class III director and R&D Committee member effective September 23, 2026
- Board appointed Alexander (Bo) Cumbo as independent Class III director through the 2028 Annual Meeting
- Leadership transition without reported disagreement, related-party transaction, or selection arrangement
- Cumbo receives $45,000 annual cash retainer and option for 39,674 shares valued at approximately $724,000
- Option vests in twelve substantially equal quarterly installments, creating shareholder dilution risk
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Stoke Therapeutics, Inc. 8-K filings
Get the next STOK 8-K as it lands
Follow STOK for push alerts, or ask the research agent what this filing means.